Back to today’s briefing

Story perspectives

Mazdutide Outshines Dulaglutide in Diabetes Trial Results

12/18/2025

24 2 Full Breakdown

Summary

Story summary

In a phase 3 trial with 731 participants among Chinese adults, Mazdutide outperformed dulaglutide in HbA1c reduction and weight loss.
HbA1c reductions were 1.57% (4 mg) and 2.15% (6 mg), vs 0.14% with placebo.
The 4 mg and 6 mg doses produced weight reductions of 5.61% and 7.81%, respectively.
Gastrointestinal side effects were common but mostly mild, and the findings suggest Mazdutide could redefine T2D management.

1 of 1

Story summary

In a phase 3 trial with 731 participants among Chinese adults, Mazdutide outperformed dulaglutide in HbA1c reduction and weight loss.
HbA1c reductions were 1.57% (4 mg) and 2.15% (6 mg), vs 0.14% with placebo.
The 4 mg and 6 mg doses produced weight reductions of 5.61% and 7.81%, respectively.
Gastrointestinal side effects were common but mostly mild, and the findings suggest Mazdutide could redefine T2D management.